From MarketBeat:

Boston Partners reduced its stock in Sanofi by 2.5% during the 3rd quarter. They sold 327,638 shares and owned 12,787,064 shares, making up 0.9% of their investment portfolio. In total, this was worth $680,697,000 as of the most recent SEC filing.

Several big investors have made changes in their holdings of Sanofi as well. BlackRock Inc. now owns 10,047,856 shares, while Morgan Stanley now owns 7,733,069 shares of the company’s stock. Bank of New York Mellon Corp holds 7,556,281 shares of the company’s stock.

Sanofi’s stock traded down to $48.64 on Thursday, with 1,172,523 shares of the company’s stock exchanged. The company has a market cap of $123.04 billion, a P/E ratio of 15.64, a PEG ratio of 2.38, and a beta of 0.61.

In terms of analyst ratings, several have been issued. Morgan Stanley initiated coverage on Sanofi with an “equal weight” rating and a $55.00 price objective for the company. JPMorgan Chase & Co. cut the company from an “overweight” rating to a “neutral” rating. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $57.50.

Sanofi is a healthcare company that operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, medicines for diabetes and cardiovascular diseases, and established prescription products.

It is important to conduct thorough research and consult financial experts before making any investment decisions, as this article does not reflect any endorsements.



Read more: Sanofi (NASDAQ:SNY) Shares Sold by Boston Partners